While Eylea (aflibercept) is taken in doses eight weeks apart, results from the YOSEMITE and RHINE studies showed faricimab produces a similar effect but with a 16-week dosing regimen. Roche’s ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and ...

Faricimab increased treatment intervals and decreased CST in previously treated nAMD patients, but BCVA remained unchanged. The study included 88 eyes from 73 patients, with a mean follow-up of 30 ...

With faricimab Roche is aiming to outperform rivals ... Supportive phase 3 trial results from the twin YOSEMITE and RHINE studies in diabetic macular oedema announced at the beginning of December ...

However, recent real-world data for faricimab has confirmed its efficacy and safety. “We’ll await longer-term data to look at really that annualized injection burden and long-term treatment ...